Live Investor briefing, page-51

Great points, Dalts. I should have read the posts you and Super posted. Could have saved myself some time and effort (for a nice change)!

We are on the same page re the value of stats. Couldn't agree more. But, as you and, I guess, Erneter, point out, staying grounded and not looking too far ahead at any one juncture is the best approach.

Your explanation re the reason for combining PTX200 with chemo makes very clear sense now. Thanks.

It was mentioned in the panel interview in which our Dan Shelly was a talking head that the FDA are giving Targeted Therapies and Universal Platforms their attention/priority (or something to that effect). This bodes well for PTX given our pipeline! Its seems really important to stay flexible and relevant in a fast-changing landscape. But I think we have to acknowledge the fact that we have a team that prioritises exactly that need. Of course, the scientific data has to keep stacking up and, so far, it seems to be tracking along fine (albeit slow recruitment for the last couple of cohorts to hit our target in PTX200).